Synergy Pharmaceuticals (FRA:S90) Other Long-Term Liabilities : €8.67 Mil (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Other Long-Term Liabilities?

Synergy Pharmaceuticals's other long-term liabilities for the quarter that ended in Sep. 2018 was €8.67 Mil.

Synergy Pharmaceuticals's quarterly other long-term liabilities declined from Mar. 2018 (€10.01 Mil) to Jun. 2018 (€8.31 Mil) but then increased from Jun. 2018 (€8.31 Mil) to Sep. 2018 (€8.67 Mil).

Synergy Pharmaceuticals's annual other long-term liabilities declined from Dec. 2015 (€0.30 Mil) to Dec. 2016 (€0.21 Mil) but then increased from Dec. 2016 (€0.21 Mil) to Dec. 2017 (€15.22 Mil).

Synergy Pharmaceuticals Other Long-Term Liabilities Historical Data

The historical data trend for Synergy Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Other Long-Term Liabilities Chart

Synergy Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Other Long-Term Liabilities

Get a 7-Day Free Trial

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Synergy Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Synergy Pharmaceuticals Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170

Website

http://www.synergypharma.com

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines